

AUG - 9 2001

8. SUMMARY OF 510(k) SAFETY AND EFFECTIVENESS

This summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The Assigned 510(k) number is: **K011730**

Submitter:

ACON Laboratories, Inc.
4108 Sorrento Valley Boulevard
San Diego, California 92121

Tel.: 858-535-2030

Fax: 858-535-2038

Date:

May 18, 2001

Contact Person:

Edward Tung, Ph.D.

Product Names:

ACON[®] PCP One Step Phencyclidine Test Strip

ACON[®] PCP One Step Phencyclidine Test Device

Common Name:

Immunochromatographic test for the qualitative detection of phencyclidine in urine

Device Classification:

The ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device are similar to other FDA-cleared devices for the qualitative detection of phencyclidine in urine specimens. These tests are used to provide a preliminary analytical result. (21 CFR 862) Phencyclidine test systems have been classified as Class II devices with moderate complexity.

Classification Name:

Phencyclidine test system

Intended Use:

The ACON[®] PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device are rapid chromatographic immunoassays for the qualitative detection of phencyclidine in urine at a cut-off concentration of 25 ng/ml. They are intended for healthcare professionals including point of care sites.

Description:

The ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device are competitive binding, lateral flow immunochromatographic assays for the qualitative screening of phencyclidine in a urine sample. The test is based on the principle of antigen-antibody immunochemistry. It utilizes the antibody to selectively detect elevated levels of phencyclidine in urine at a cut-off concentration of 25 ng/ml. These tests can be performed without the use of an instrument.

A drug-positive urine specimen will not generate a red-colored line in the designated test region, while a negative urine specimen will generate a red-colored line in the test region. To serve as a procedural control, a red-colored line will always appear at the control region if the test has been performed properly.

Predicate Device:

LifeSign Status DS[™] PCP One-Step Phencyclidine Test

510(k) Number: K961266

Distributor:

LifeSign, LLC

71 Veronica Avenue

Somerset, New Jersey 08873

Comparison to a Predicate Device:

A comparison of the features of the ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device versus the LifeSign Status DS[™] PCP One-Step Phencyclidine Test is shown below:

- Both tests are assays intended for the qualitative detection of phencyclidine in urine samples.
- Both tests are intended as a screening method that provides a preliminary analytical test result.
- Both tests are immunochromatographic, lateral flow assays for the rapid detection of phencyclidine with a visual, qualitative end result.
- Both tests utilize the same basic immunoassay principles that rely on antigen/ antibody interactions to indicate a positive or negative result.
- Both tests have a cut-off phencyclidine concentration of 25 ng/ml.

Safety and Effectiveness Data:

Accuracy

A clinical evaluation was conducted using 212 clinical urine specimens which included 10% samples with the drug concentrations at -25% cutoff to +25% cutoff. This evaluation compared the test results of the ACON[®] PCP One Step Phencyclidine Test Strip and the ACON PCP One Step Phencyclidine Test Device against the LifeSign Status DS[™] PCP One-Step Phencyclidine Test, as well as against the customary Gas Chromatography/Mass Spectrometry analysis. The comparisons of data obtained from this study yielded the following results:

ACON PCP One Step Phencyclidine Test Strip versus the LifeSign Status DS[™] PCP One-Step Phencyclidine Test:

Positive Agreement: $56 / 57 = 98\%$ (91% - 100%*)
Negative Agreement: $155 / 155 = 100\%$ (98% - 100%*)
Overall Agreement: $211 / 212 = 99.5\%$ (97% - 100%*)

* 95% confidence intervals

ACON PCP One Step Phencyclidine Test Device versus the LifeSign Status DS[™] PCP One-Step Phencyclidine Test:

Positive Agreement: $55 / 57 = 97\%$ (88% - 100%*)
Negative Agreement: $155 / 155 = 100\%$ (98% - 100%*)
Overall Agreement: $210 / 212 = 99\%$ (97% - 100%*)

* 95% confidence intervals

ACON PCP One Step Phencyclidine Test Strip versus GC/MS at the cutoff of 25 ng/ml:

Positive agreement with GC/MS: $50 / 50 = 100\%$ (93% - 100%) *
Negative agreement with GC/MS: $156 / 162 = 96\%$ (92% - 99%) *
Total agreement with GC/MS: $206 / 212 = 97\%$ (94% - 99%) *

* 95% confidence intervals

ACON PCP One Step Phencyclidine Test Device versus GC/MS at the cutoff of 25 ng/ml:

Positive agreement with GC/MS: $50 / 50 = 100\%$ (93% - 100%) *
Negative agreement with GC/MS: $157 / 162 = 97\%$ (93% - 99%) *
Total agreement with GC/MS: $207 / 212 = 98\%$ (94% - 99%) *

* 95% confidence intervals

Conclusion:

These studies demonstrate the substantial equivalency between the ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device and the LifeSign Status DS[™] PCP One-Step Phencyclidine Test, which has already being marketed in the United States. It is also demonstrated that these tests are safe and effective in detecting phencyclidine at a concentration of 25 ng/mL. The POL study demonstrated that these tests are suitable for Health professionals including point-of-care sites.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

AUG - 9 2001

Edward Tung, Ph.D.
Director of Regulatory Affairs
ACON Laboratories, Inc.
4108 Sorrento Valley Blvd.
San Diego, CA 92121

Re: 510(k) Number: K011730
Trade/Device Name: ACON® PCP One Step Phencyclidine Test Strip and ACON® PCP
One Step Phencyclidine Test Device
Regulatory Class: II
Product Code: LCM
Dated: June 1, 2001
Received: June 5, 2001

Dear Dr. Tung:

We have reviewed your Section 510(k) notification of intent to **market the device** referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

10. INDICATIONS FOR USE

510(k) Number: K011730

Device Name: ACON® PCP One Step Phencyclidine Test Strip

ACON® PCP One Step Phencyclidine Test Device

Indications for Use:

The ACON PCP One Step Phencyclidine Test Strip and ACON PCP One Step Phencyclidine Test Device are rapid chromatographic immunoassays for the qualitative detection of phencyclidine in human urine at a cut-off concentration of 25 ng/mL. They are intended for healthcare professionals including point of care sites.

Jean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K011730

(Please do not write below this point)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒

Or

Over-The-Counter Use ☐

(Per 21 CFR 801.109)

Keria Alexander for Jean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K011730